Meeting
2018 Gastrointestinal Cancers Symposium
Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis.
Authors
Jacqueline N. Chu
Massachusetts General Hospital, Boston, MA
Jacqueline N. Chu , Jin G. Choi , Sassan Ostvar , James A. Torchia , Kerry Lynn Reynolds , Justin F. Gainor , Daniel C. Chung , Jeffrey W. Clark , Chin Hur
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 829)
DOI
10.1200/JCO.2018.36.4_suppl.829
Abstract #
829
Poster Bd #
N5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Relationship between the number of positive MSI markers and the efficacy of NIVO+IPI therapy in MSI-H gastric cancer: A subgroup analysis of NO LIMIT study (WJOG13320G/CA209-7W7).
First Author: Kenro Hirata
Poster
2023 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
First Author: Heinz-Josef Lenz